The FDA and CDC both approved the updated bivalent COVID-19 vaccines last week. The promise of the mRNA vaccine technology platform was always that we could update them quickly. We may finally have achieved an advantage over SARS-COV-2 as the updated vaccine recipe matches the current dominant circulating BA.5 strain (and slow growing BA.4.6 strain) without another more transmissible variant of concern yet on the horizon.